Parkin­son's pa­tients no longer need to re­ly on a nee­dle for apo­mor­phine an­ti­dote for 'of­f' episodes af­ter new FDA ap­proval

A mor­phine de­riv­a­tive — usu­al­ly in­ject­ed or in­fused — used to treat “off” episodes in Parkin­son’s is now up for grabs in a con­ve­nient un­der-the-tongue dis­solv­able for­mu­la­tion, mak­ing life much eas­i­er for pa­tients when flares strike.

Sunovion, a com­pa­ny formed in 2009 by the fu­sion of Sepra­cor and the US op­er­a­tions of Sum­it­o­mo Dainip­pon Phar­ma, has se­cured the ap­proval of the sub­lin­gual for­mu­la­tion about a year and a half fol­low­ing an ini­tial re­jec­tion by the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER